# US 2021/0332347 A1 · Methods for targeted insertion of dna in genes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332347 A1
- Document ID: US20210332347A1
- Status: Published application
- Kind: A1
- Application number: 17/366,290
- Filed: 2021-07-02
- Published: 2021-10-28
- Earliest claimed: 2018-10-16
- Assignees: Blueallele Corporation
- Applicants: Blueallele Corporation
- Inventors: Nicholas J. BALTES
- Web page: https://patentgrep.com/patent/US20210332347A1

## CPC

- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/86: Viral vectors
- C12N 15/902: {using homologous recombination}
- C12N 15/907: {in mammalian cells}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N 2840/44: being a specific part of the splice mechanism, e.g. donor, acceptor
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Methods and compositions for modifying the coding sequence of endogenous genes using rare-cutting endonucleases and transposases. The methods and compositions described herein can be used to modify the coding sequence of endogenous genes.

## Claims

### Claim at position 1

1-17. (canceled)

### Claim 18

A recombinant nucleic acid comprising a transgene, the transgene comprising in 5′ to 3′orientation:
a first splice acceptor, a first coding sequence, a first terminator, a second terminator reverse complement, a second coding sequence reverse complement, and a second splice acceptor reverse complement,
wherein the first coding sequence encodes an amino acid sequence, and the second coding sequence encodes the same amino acid sequence as the first coding sequence.

### Claim 19 (depends on 18)

The recombinant nucleic acid of claim 18, wherein the first coding sequence and second coding sequence comprise different polynucleotide sequences, but each encodes the same amino acid sequence.

### Claim 20 (depends on 18)

A recombinant non-viral vector comprising the recombinant nucleic acid of claim 18.

### Claim 21 (depends on 18)

A recombinant viral vector comprising the recombinant nucleic acid of claim 18.

### Claim 22 (depends on 21)

The viral vector of claim 21, wherein the viral vector is selected from the group consisting of an adenovirus vector, an adeno-associated virus vector, and a lentivirus vector.

### Claim 23 (depends on 18)

The recombinant nucleic acid of claim 18, wherein the first coding sequence and second coding sequence each encode a peptide produced by exon 10 of a non-pathogenic ATXN3 gene.

### Claim 24 (depends on 18)

The recombinant nucleic acid of claim 18, wherein the first coding sequence and second coding sequence each encode a peptide produced by exon 47 of a non-pathogenic CACNA1A gene.

### Claim 25 (depends on 18)

The recombinant nucleic acid of claim 18, wherein the first coding sequence and second coding sequence each encode a peptide produced by a gene selected from Factor V, Factor VII, Factor XIII, Factor IX, Factor X, Factor XI, Factor XII, Factor XIII, an LDL Receptor, and TTR.

### Claim 26 (depends on 18)

The recombinant nucleic acid of claim 18, wherein the recombinant nucleic acid is equal to or less than 4.7 kb.

### Claim 27

A cell comprising a transgene, wherein the transgene is integrated into an endogenous gene, said transgene comprising in 5′ to 3′ orientation:
a first splice acceptor, a first coding sequence, a first terminator, a second terminator reverse complement, a second coding sequence reverse complement, and a second splice acceptor reverse complement,
wherein the first coding sequence encodes an amino acid sequence heterologous to the cell, and the second coding sequence encodes the same heterologous amino acid sequence.

### Claim 28 (depends on 27)

The cell of claim 27, wherein the first coding sequence or second coding sequence of the transgene is operably linked to a promoter of the endogenous gene.

### Claim 29 (depends on 28)

The cell of claim 28, wherein the first coding sequence and second coding sequence of the transgene comprise different polynucleotide sequences, but each encodes the same heterologous amino acid sequence.

### Claim 30 (depends on 28)

The cell of claim 28, wherein the first coding sequence and second coding sequence each encode a peptide selected from Factor V, Factor VII, Factor XIII, Factor IX, Factor X, Factor XI, Factor XII, Factor XIII, an LDL Receptor, and TTR.

### Claim 31 (depends on 28)

The cell of claim 28, wherein the first coding sequence and second coding sequence each encode a peptide produced by exon 10 of a non-pathogenic ATXN3 gene.

### Claim 32 (depends on 28)

The cell of claim 28, wherein the first coding sequence and second coding sequence each encode a peptide produced by exon 47 of a non-pathogenic CACNA1A gene.

### Claim 33

A recombinant nucleic acid comprising a transgene, the transgene comprising in 5′ to 3′orientation:
a first splice acceptor, a first coding sequence, a first terminator, a second terminator reverse complement, a second coding sequence reverse complement, and a second splice acceptor reverse complement,
wherein the first coding sequence encodes an amino acid sequence, and the second coding sequence encodes the same amino acid sequence as the first coding sequence, and
wherein the recombinant nucleic acid is linear or circular.

### Claim 34 (depends on 33)

The recombinant nucleic acid of claim 33, wherein the nucleic acid is in a circular conformation.

### Claim 35 (depends on 33)

The recombinant nucleic acid of claim 33, wherein the first coding sequence and second coding sequence comprise different polynucleotide sequences, but each encodes the same amino acid sequence.

### Claim 36 (depends on 33)

A viral vector comprising the recombinant nucleic acid of claim 33.

### Claim 37 (depends on 36)

The viral vector of claim 36, wherein the viral vector is selected from the group consisting of an adenovirus vector, an adeno-associated virus vector, and a lentivirus vector.
